Integrating cell-level kinetic modeling into the design of engineered protein therapeutics.
about
Structure-based Protocol for Identifying Mutations that Enhance Protein–Protein Binding AffinitiesStructural Determinants of Affinity Enhancement between GoLoco Motifs and G-Protein Subunit MutantsPredicting essential components of signal transduction networks: a dynamic model of guard cell abscisic acid signaling.Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell cIntracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer.Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modellingSelection and characterization of the novel anti-human PD-1 FV78 antibody from a targeted epitope mammalian cell-displayed antibody library.Cellular level models as tools for cytokine design.Dynamics of biological systems: role of systems biology in medical research.Multiscale models of breast cancer progressionTranslational potential of systems-based models of inflammationAt the bench: the key role of PK-PD modelling in enabling the early discovery of biologic therapiesKinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability.Inhibition of transferrin iron release increases in vitro drug carrier efficacyFluorogenic dendrons with multiple donor chromophores as bright genetically targeted and activated probes
P2860
Q27646507-841973CB-FF35-488A-ABDE-340A6FF86BE1Q27666097-A2E6BEA3-01AC-4709-8666-968D1086EE1EQ33257261-60D18949-0B73-4900-BCD0-D2F3FC85B969Q33917876-EF4D757D-A868-4B8A-876A-7056D1F55259Q33995700-DD6D6D58-4319-4D12-B4FC-455CCB48EA09Q34751465-8B78D8D7-F835-45A1-99D1-8CD1C15AD6B5Q35905876-7F585AF1-99E2-4AD8-9C89-86352FB2461CQ36097041-245CF82B-9CFA-4AF4-98F8-0AAC7EF4A8B7Q36393660-60DAA870-696D-43D9-A209-F956C7AECC68Q36670951-F3FF3904-175A-4BBE-9172-1C02DA14B8E4Q37404422-1B13CBD6-E7E1-4A65-B375-65C31E95A4B6Q37742690-D1AC4FC9-23FF-4219-80C6-ABA59F328AC4Q38130330-783721A3-279B-4964-9E32-83BBA4C928FCQ39668471-4AD7B0AA-A050-45B3-BE2D-C713DDB7A07BQ41831883-1F5C32E2-2B09-46AB-B41F-7999D28B6384Q42200160-B61A4CCF-C0EE-43A1-97C3-47551BBB53BA
P2860
Integrating cell-level kinetic modeling into the design of engineered protein therapeutics.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Integrating cell-level kinetic ...... gineered protein therapeutics.
@en
Integrating cell-level kinetic ...... gineered protein therapeutics.
@nl
type
label
Integrating cell-level kinetic ...... gineered protein therapeutics.
@en
Integrating cell-level kinetic ...... gineered protein therapeutics.
@nl
prefLabel
Integrating cell-level kinetic ...... gineered protein therapeutics.
@en
Integrating cell-level kinetic ...... gineered protein therapeutics.
@nl
P2860
P356
P1433
P1476
Integrating cell-level kinetic ...... gineered protein therapeutics.
@en
P2093
Balaji M Rao
K Dane Wittrup
P2860
P2888
P304
P356
10.1038/NBT1064
P577
2005-02-01T00:00:00Z